Cholesteryl ester transfer protein, high density lipoprotein and arterial disease.
The reported relationships between cholesteryl ester transfer protein, high density lipoproteins and arterial disease are confusing and conflicting. Several papers published during the review period add substantially to the evidence base regarding the atherogenicity (or anti-atherogenicity) of cholesteryl ester transfer protein, although none clearly resolves the continuing conflict. These new papers are presented against the backdrop of the previous state of knowledge.
Barter
P J
PJ
Hanson Centre and the Cardiovascular Investigation Unit, Royal Adelaide Hospital and the Department of Medicine, University of Adelaide, South Australia 5000. philip.barter@adelaide.edu.au
Rye
K A
KA
D000818:Animals; D001161:Arteriosclerosis / Q000209:etiology / Q000235:genetics; D002352:Carrier Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology; D053480:Cholesterol Ester Transfer Proteins; D020022:Genetic Predisposition to Disease; D006023:Glycoproteins; D006801:Humans; D008075:Lipoproteins, HDL / Q000097:blood; D016376:Oligonucleotides, Antisense / Q000494:pharmacology; D011110:Polymorphism, Genetic
C506642:CETP protein, human; D002352:Carrier Proteins; D053480:Cholesterol Ester Transfer Proteins; D006023:Glycoproteins; D008075:Lipoproteins, HDL; D016376:Oligonucleotides, Antisense